Home
NewsNewsCDSCO Orders on IVF Medical Devices reinforce strict regulatory oversight across India’s fertility sector. The directive mandates licensing compliance under existing laws, ensuring IVF and ART devices meet safety and quality standards. This move aims to curb unauthorized sales, strengthen enforcement, and bring greater accountability to medical device usage in reproductive healthcare.
Through a recent notice, the Central Drugs Standard Control Organization (CDSCO) has directed strict regulatory oversight on the import, manufacture, sale, and distribution of medical devices used in In Vitro Fertilization (IVF) and Assisted Reproductive Technology (ART) procedures. This move, highlighted under CDSCO Orders on IVF Medical Devices, reinforces the need for compliance across the sector.
The directive highlights that all medical devices are regulated under the provisions of the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017, and require appropriate licensing for import, manufacturing, sale, and distribution, except for Class A non-sterile and non-measuring medical devices. Under the CDSCO Orders on IVF Medical Devices, adherence to these frameworks has been strongly reiterated.
It further clarifies that devices used in IVF procedures, including IUI (Intrauterine Insemination) kits and centrifuges for sperm washing, fall within the definition of medical devices under the existing regulatory framework. The CDSCO has taken note of instances where firms are selling medical devices intended for In Vitro Fertilization viz., IUI (Intrauterine Insemination) kits, centrifuges for sperm washing, etc., used for Assisted Reproductive Technology related procedures without obtaining a licence from the licensing authority under the Medical Devices Rules, 2017.
In response, the apex drug regulator has instructed all State and Union Territory drug control and licensing authorities to maintain strict vigilance and ensure that no such devices are imported, manufactured, distributed, or sold without compliance with the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017. This enforcement push forms a critical part of the ongoing CDSCO Orders on IVF Medical Devices.
The notice concluded by directing all State/UT Drugs Control and Licensing Authorities, Zonal, Sub-Zonal and Port Offices of the Central Drugs Standard Control Organization (CDSCO), as well as stakeholders through its official website, stating: "You are requested to keep strict vigil & ensure that no such devices used for In Vitro Fertilization for Assisted Reproductive Technology related procedures are being imported, manufactured, distributed, sold without bidance to the Drugs and Cosmetics Act,1940 and Medical Devices Rules, 2017."
The circular has been addressed to all State/UT Drugs Control and Licensing Authorities, along with all Zonal, Sub-Zonal, and Port Offices of CDSCO. It has also been shared with stakeholders via the CDSCO website for wider awareness and compliance.
A new Ipsos survey commissioned by Fertility Matters Canada finds 49% of Canadians with an opinion support a national baseline for IVF funding support, with backing rising to 59% among those aged 18–34. One in eight Canadians say cost has already forced them or someone close to delay or abandon fertility treatment.
Alpha Controls & Instrumentation Inc. has been selected by FertiTech Canada Inc. as its third-party calibration partner for Nilotech temperature probes. The partnership channels Canadian IVF laboratories and fertility clinics using Nilotech equipment to Alpha Controls for professional, accredited calibration services, while FertiTech continues to handle equipment supply and gas sensor calibration.
In the UK, a Ten Minute Rule Bill has been introduced in the Commons to create a legal right to paid time off for fertility treatment, aiming to standardize access to time‑sensitive appointments and reduce reliance on employer discretion. The proposal seeks House permission to proceed and spotlights workplace rights during Fertility Awareness Week.
Columbia University Fertility Center has achieved the first confirmed pregnancy using an AI-guided sperm recovery method in a man with azoospermia, as detailed in The Lancet. The STAR system combined advanced imaging, microfluidics, and robotics to retrieve two viable sperm, enabling embryo creation after prior failed surgical and manual attempts.
British Columbia's free IVF program exhausts 2025 funding within months of launch. At least one approved clinic stops accepting new applications. Applicants face aging-out risks and must wait until spring 2026 for next funding allocation.
Singapore’s MOH approves 13 additional genetic conditions for testing before embryos are implanted during IVF, enhancing reproductive genetic screening options.
National Health Service-funded IVF in England varies across regions in terms of access, cycle definitions, and eligibility. While Integrated Care Boards follow NICE guidelines, local implementation differs to meet specific population needs. Current policy reviews aim to enhance consistency and ensure continued access to fertility services across England.
